Tekla Life Sciences Investors (NYSE:HQL) — Stock Price
Tekla Life Sciences Investors (NYSE:HQL) is currently trading at $20.82 USD, up 0.97% today. Over the past 52 weeks, shares have ranged between $13.36 and $20.83. This page tracks Tekla Life Sciences Investors's live share price on the NYSE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Tekla Life Sciences Investors market capitalisation.
Tekla Life Sciences Investors (HQL) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Tekla Life Sciences Investors's daily closing share price and trading volume on the NYSE exchange over the past year, giving a clear view of recent price momentum and liquidity.
Tekla Life Sciences Investors Income Statement — Revenue, Profit & Earnings by Year
Tekla Life Sciences Investors's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $86.39 Million | $86.69 Million | $23.52 Million | $-103.25 Million | $65.69 Million |
| Cost of Revenue | — | — | $5.24 Million | $5.55 Million | $5.60 Million |
| Gross Profit | $86.39 Million | $86.69 Million | $23.52 Million | $-103.25 Million | $65.69 Million |
| Research & Development | — | — | $0.57 | $3.28 | $1.43 |
| SG&A | $743.17K | $1.33 Million | $903.14K | $1.08 Million | $844.02K |
| Total Operating Expenses | $791.57K | $1.39 Million | $1.17 Million | $1.35 Million | $1.16 Million |
| Operating Income | $85.59 Million | $85.30 Million | $22.35 Million | $-104.60 Million | $64.53 Million |
| EBITDA | $85.59 Million | $87.22 Million | $22.35 Million | $-104.60 Million | $64.53 Million |
| EBIT | — | $85.30 Million | $22.35 Million | $-104.60 Million | $64.53 Million |
| Interest Expense | — | — | — | — | $0.00 |
| Income Before Tax | $85.59 Million | $85.30 Million | $22.35 Million | $-104.60 Million | $64.53 Million |
| Income Tax Expense | — | — | $22.35 Million | $-2.99 Million | $-4.15 Million |
| Net Income | $85.59 Million | $85.30 Million | $22.35 Million | $-104.60 Million | $64.53 Million |
Tekla Life Sciences Investors Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Tekla Life Sciences Investors's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $515.38 Million | $460.58 Million | $402.60 Million | $414.73 Million | $534.19 Million |
| Total Current Assets | $1.25 Million | $281.61K | $5.05 Million | $623.92K | $144.66K |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | $17.23 Million | $15.24 Million | $32.94 Million | $17.17 Million |
| Net Receivables | $1.14 Million | $231.11K | $5.04 Million | $623.47K | $150.34K |
| Inventory | — | — | $20.29 Million | $33.57 Million | $17.32 Million |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $1.73 Million | $888.61K | $666.96K | $16.82 Million | $10.75 Million |
| Total Current Liabilities | $720.90K | $888.61K | — | $5.10 Million | $10.75 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | $-75.54K | $-1.00 | $-477.00 | $10.65K | $1.34 Million |
| Total Stockholder Equity | $513.66 Million | $459.69 Million | $401.93 Million | $397.90 Million | $523.44 Million |
| Retained Earnings | $77.60 Million | $44.13 Million | $-1.48 Million | $9.55 Million | $150.70 Million |
Tekla Life Sciences Investors Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Tekla Life Sciences Investors generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2021 | 2019 | 2014 | 2013 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-2.32 Million | $-0.74 | $-0.62 | $-52.57K | $9.47K |
| Capital Expenditures | $5.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Free Cash Flow | $-2.32 Million | $-0.74 | $-0.62 | $-52.57K | $9.47K |
| Investing Cash Flow | $25.21 Million | — | — | — | — |
| Financing Cash Flow | $-31.63 Million | — | — | $52.53K | $-9.44K |
| Dividends Paid | $31.63 Million | — | — | $13.96K | $9.44K |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | — | — | — | — | — |
| Change in Cash | $75.54K | $-0.74 | $1.12 Million | $-34.24 | $35.89 |
Tekla Life Sciences Investors Earnings History — EPS Actual vs. Analyst Estimates
Track Tekla Life Sciences Investors's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Dec 08, 2025 | 4.38 | 0.00 | — |
| Jun 09, 2025 | -1.64 | — | — |
| Dec 09, 2024 | 1.22 | 0.00 | — |
| Dec 07, 2022 | -1.08 | 0.00 | — |
| Jun 03, 2022 | -3.03 | 0.00 | — |
| Dec 03, 2021 | 1.32 | 0.00 | — |
| Sep 30, 2021 | 0.67 | 0.00 | — |
| Jun 04, 2021 | 1.30 | 0.00 | — |